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Ability of a biomarker-based score to predict
death from circulatory disease and cancer in
NHANES III
Mieke Van Hemelrijck1*, Monika Eichholzer2, David Faeh2 and Sabine Rohrmann2
Abstract
Background: A score based on serum concentrations of C-reactive protein (CRP), albumin, gamma-glutamyl
transferase (GGT), and HDL cholesterol was positively associated with death from cancer, circulatory disease, and
all-cause mortality. We replicated this in the third National Health and Nutrition Examination Survey (NHANES III), a
US nationally representative survey conducted between 1988–1994.
Methods: Baseline measurements of CRP, albumin, GGT, and HDL were available for participants with mortality
follow-up (n=13,056). A biomarker score, ranging 0–4, was created by adding number of markers with abnormal
values (cut-off: CRP>10mg/L, albumin<35mg/L, GGT>36U/L, HDL<1.04mmol/L). Its association with mortality was
analyzed with multivariate Cox proportional hazards models.
Results: The score was positively associated with death from all causes, cancer and circulatory disease [e.g. HR
all-cause mortality: 1.21 (95% CI: 1.09, 1.35), 1.92 (1.67, 2.20), 3.38 (2.62, 4.36), and 7.93 (5.77, 10.89), for score 1, 2, 3, 4
vs.0]. These patterns were found across the Charlson Comorbidity Index (CCI). Where CCI =3, risk of cancer death
was 1.09 (0.93, 1.28), 1.81 (1.43, 2.29), 4.67 (3.05, 7.14), and 6.97 (5.32, 9.14) for score 1, 2, 3, 4 vs. 0. No
effect-modification by sex or race/ethnicity was observed.
Conclusions: These findings correlate with results from a Swedish study. This biomarker-based score could help
clinicians make decisions in prevention and disease management.
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Background
In a large prospective cohort study from Sweden, the
combination of easily and inexpensively measurable
biomarkers clearly predicted mortality in persons aged
50+ years [1]. This mortality score included serum
levels of C-reactive protein (CRP), albumin, gamma-
glutamyltransferase (GGT), and high-density lipoprotein
(HDL) cholesterol, all reflecting possible mechanisms
contributing to early death: inflammation [2,3], hepatic
function [4], and lipid metabolism [5,6]. The score was
positively and progressively associated with all-cause
mortality as well as cancer and circulatory disease-
specific death. Even among cancer patients with no
other co-morbidities, according to the Charlson
Comorbidity Index (CCI), the score was predictive for
mortality [1]. The mortality score’s ability to predict
death is important, especially given the need for an as-
sessment of functional rather than chronological age
when treating cancer patients, as recently expressed by
the European Organization for Research and Treatment
of Cancer (EORTC) Elderly Task Force [7]. Following
the rising life expectancy in many countries, it is of im-
portance to accurately predict cancer burden among
aging cancer populations suffering from concomitant
disease at time of cancer diagnosis.
We examined the association of this biomarker-based
score with mortality and with respect to CCI and other
potential modifying factors among 13,056 participants in
the Third National Health and Nutrition Examination
Survey (NHANES III), a large study designed to be na-
tionally representative of the United States population.
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Methods
Study population and data collection
This study is based on the NHANES III Mortality link-
age which provides follow-up data from the date of
NHANES III survey participation (1988–1994) through
December 31, 2006.
NHANES III is a cross-sectional study conducted by
the National Center for Health Statistics (NCHS) be-
tween 1988 and 1994 [8]. It was designed as a multistage
stratified, clustered probability sample of the US civilian
non-institutionalized population at least two months old.
Subjects participated in an interview conducted at home
and an extensive physical examination, which included a
blood sample, conducted in a mobile examination center
[8]. NHANES III was conducted in two phases (1988–
1991 and 1991–1994). Unbiased national estimates of
health and nutrition characteristics can be independently
produced for each phase. Within each phase, subjects
were randomly assigned to participate in either the
morning or afternoon/evening examination session. In
total, 30,818 people were interviewed in NHANES III
and had a physical examination and a blood sample
taken. The NCHS has updated the mortality linkage of
NHANES III to death certificate data found in the Na-
tional Death Index (NDI) so that mortality ascertainment
is based upon the results from a probabilistic match be-
tween NHANES III and NDI death certificate records
[9]. From this linkage, we selected all men and women
eligible for mortality follow-up (all participants 17 years
of older) with baseline measurements of CRP, GGT,
HDL, and albumin (n=13,056).
Serum CRP was quantified using latex-enhanced nephe-
lometry, standardized according to the World Health
Organization's international reference preparation of CRP
with the coefficient of variation ranging from 3.2–16.1%
(median, 6.3%) through the study period [10]. Serum GGT
concentration was assayed with a Hitachi 737 Analyzer
(Boehringer–Mannheim Diagnostics, Indianapolis, IN,
USA) with coefficients of variation ranging from 1.9 to
3.5% [10]. HDL cholesterol was measured using standard
enzymatic methods and serum albumin was assessed with
the bromcresol purple method. Details about all laboratory
procedures have been published elsewhere [10].
Other covariates in the analysis included age, race/
ethnicity, poverty-to-income-ratio, comorbidity index,
smoking, alcohol consumption, and physical activity.
Race and ethnicity were combined into four race–ethnic
groups: Non-Hispanic white, Non-Hispanic black,
Mexican American and Other. The poverty to income
ratio is an index of poverty status which is calculated
by dividing family income by a poverty threshold spe-
cific to family size.
Comorbidity was evaluated with a comorbidity coeffi-
cient similar to the CCI, as used in other NHANES III-
based analyses [11]. Each of the comorbidities available
in the dataset contributed one point to the composite
index with additional points given for older age.
Cigarette smoking, alcohol consumption, and physical
activity were assessed using questionnaires. The proto-
cols for the conduct of NHANES III were approved by
the institutional review board of the National Center for
Health Statistics, Centers for Disease Control and Pre-
vention. Written informed consent was obtained from
all participants.
Data analysis
To address the combined association between the four
biomarkers of interest and all-cause mortality we started
with a multivariate Cox proportional hazards regression
using continuous variables of CRP (mg/L), albumin
(g/L), GGT (U/L), and HDL (mmol/L). A mortality
score, ranging from 0 to 4, was then calculated as the
number of biomarkers with abnormal values according
to their clinical cut-offs (CRP>10mg/L, albumin<35g/L,
GGT>35U/L, and HDL<1.03mmol/L) [3,12,13]. Multi-
variate Cox proportional hazards regression was used to
investigate this mortality score in relation to all-cause
mortality as well as cancer-specific (ICD10:C00-C99)
and circulatory-specific death (ICD10: I00-I99). Sam-
pling weights for NHANES III were used to account for
sampling variability and to adjust for differential prob-
ability of selection of persons [8]. All models were
adjusted for age (continuous), race/ethnicity, poverty to
income ratio, comorbidity index, smoking, alcohol con-
sumption, physical activity, and BMI. A test for trend
was conducted by using assignment to quartiles as an
ordinal scale, meaning a continuous variable ranging
from 1 to 4 indicating the different quartiles. Stratified
analyses were conducted for men and women [14], age-
groups (<65 and 65+), different categories of the CCI,
and ethnic groups. The latter offers the opportunity to
evaluate whether the score holds across different ethnic
groups and is in concordance with many other studies
performed in NHANES [15-17]. We also assessed the
association between the mortality score and the CCI by
calculating the correlation coefficient and kappa’s coeffi-
cient of agreement between both measurements. All
tests were two-sided; p-values <0.05 were considered to
be statistically significant. All analyses were conducted
with Statistical Analysis Systems (SAS) release 9.1.3
(SAS Institute, Cary, NC).
Results
A total of 3,081 persons died during follow-up time, of
whom 653 (21.19 %) died of cancer and 1,388 (45.05%)
of circulatory disease. Population characteristics are
shown in Table 1. A higher CCI was observed for those
who died during follow-up than for those who were alive
Van Hemelrijck et al. BMC Public Health 2012, 12:895 Page 2 of 9
http://www.biomedcentral.com/1471-2458/12/895
at the end of follow-up (32.91% versus 8.11% with
CCI=4+) (Table 1).
A multivariate Cox proportional hazards model in-
cluding continuous variables of CRP (mg/L), albumin
(g/L), GGT (U/L), and HDL (mmol/L) showed that CRP
and GGT were statistically significantly associated with
all-cause mortality: HR per one unit increase: 1.19 (95%
CI: 1.11, 1.27), 0.95 (0.93, 0.96), 1.31 (1.25, 1.39), and
0.98 (95%CI: 0.91, 1.05), respectively. A log transform-
ation was performed for CRP, GGT, and HDL due to
their skewed distributions.
When using the mortality score, there was a statisti-
cally significant positive association between the score
and all-cause mortality as well as cancer and circulatory
disease-specific death (e.g. HR for all-cause mortality:
1.21 (95%CI: 1.09, 1.35), 1.92 (95%CI: 1.67, 2.20), 3.38
(95%CI: 2.62, 4.36), and 7.93 (95%CI: 5.77, 10.89) for
score=1, 2, 3 and 4 compared to score=0). Similar pat-
terns were found when stratifying by sex and age groups
(Table 2 and 3). Figure 1 also shows how each marker of
the mortality score contributes to the risk of death.
There is no clear pattern by specific biomarkers, but
GGT and albumin seem to contribute more than CRP
and HDL cholesterol.
To compare the mortality score with the more com-
monly used CCI, we estimated the association between
the CCI and all-cause mortality, which showed analo-
gous risks (HR: 1.06 (95%CI: 0.45, 2.49), 1.55 (95%CI:
0.65, 3.71), and 2.41 (95%CI: 1.00, 5.76) for CCI=2, 3,
and 4+ compared to CCI=0; P for trend<0.001). Effect
modification by CCI for the association between the
mortality score and risk of dying was then assessed with
Table 1 Descriptive statistics of study population by vital
status
Survivors
(N=9,975)
Deaths from all
causes (N=3,081)
Mean Age (years) (SE) 39.14 (0.31) 65.53 (0.55)
Gender
Men 47.48 49.50
Women 52.52 50.50
Mean follow-up time
(months) (SE)
174.14 (2.60) 95.17 (1.91)
Race - Ethnicity
Non-Hispanic white 74.40 80.71
Non-Hispanic black 10.98 11.99
Mexican American 5.33 2.53
Other 9.28 4.78
Poverty to income ratio
<1.4 18.66 25.98
1.4-3.17 33.47 37.10
≥3.17 47.87 36.92
Comorbidity Index (CCI)
0 0.43 0.08
2 69.22 32.32
3 22.85 35.05
4+ 7.51 32.55
Alcohol consumption
Never 42.54 62.34
Up to once a week 20.27 13.77
2-3 times a week 15.27 6.70
4-6 times a week 12.33 6.47
Daily or more 9.59 10.72
Smoking behaviour
Never 49.59 37.49
Former 22.57 35.68
Current 27.84 26.83
Vigorous Physical activity 8.44 24.91
BMI (kg/m2)
<18.50 2.53 3.37
18.50-24.99 44.38 35.16
25.00-29.99 31.71 35.67
>30.00 21.38 25.80
CRP (mg/l)
Mean (SE) 0.38 (0.01) 0.66 (0.02)
>10 5.40 14.94
Albumin (g/l)
Mean (SE) 41.88 (0.17) 40.00 (0.17)
<35 2.28 6.50
Table 1 Descriptive statistics of study population by vital
status (Continued)
HDL-cholesterol (mmol/L)
Mean (SE) 106.81 (39.29) 94.02 (35.09)
<1.03 22.48 28.38
Gamma-glutamyltransferase (U/L)
Mean (SE) 27.85 (0.54) 38.71 (1.28)
>36 16.80 25.23
Mortality score
0 61.60 47.11
1 30.54 34.95
2 7.18 14.35
3 0.65 2.99
4 0.02 0.61
Cancer-specific death
(ICD10: C00-C99)
24.01
Circulatory death
(ICD10: I00-I99)
41.53
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Table 2 Hazard Ratio (HR) and 95% Confidence Intervals (CI) for risk of all-cause, cancer-specific, and circulatory disease death
Total Men Women
All-cause Cancer Circulatory All-cause Cancer Circulatory All-cause Cancer Circulatory
HR 95%CI HR 95%CI HR 95%CI HR 95%CI HR 95%CI HR 95%CI HR 95%CI HR 95%CI HR 95%CI
Score=0 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref
Score=1 1.21 1.09, 1.35 1.12 0.91, 1.38 1.28 1.08, 1.51 1.16 1.00, 1.34 1.28 1.00, 1.64 1.18 0.97, 1.43 1.25 1.09, 1.43 0.98 0.70, 1.37 1.34 1.06, 1.70
Score=2 1.92 1.67, 2.20 1.33 0.92, 1.93 2.20 1.85, 2.62 1.64 1.33, 2.02 1.14 0.72, 1.80 1.92 1.55, 2.37 2.40 1.90, 3.04 1.85 0.97, 3.51 2.52 1.82, 3.46
Score=3 3.38 2.62, 4.36 2.03 1.33, 3.08 3.80 1.82, 6.29 4.13 2.94, 5.80 2.45 1.38, 4.35 3.40 1.74, 6.63 2.43 1.71, 3.46 1.45 0.84, 2.50 2.99 1.71, 7.63
Score=4 7.93 5.77, 10.89 5.63 3.75, 8.43 8.84 4.78, 16.37 6.13 3.76, 9.97 5.14 1.68, 15.70 7.56 4.00, 14.31 9.80 6.98, 13.75 5.90 3.56, 9.77 10.58 5.01, 22.35
P for trend <0.001 0.007 <0.001 <0.001 0.030 <0.001 <0.001 0.080 <0.001
All models were adjusted for age, gender, poverty to income ratio, race ethnicity group, smoking behavior, alcohol consumption, vigorous physical activity, BMI, and Charlson Comorbidity Index.
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stratified analyses by categories of CCI (Table 4). The
patterns observed in Table 2 were seen in each cat-
egory of CCI, even among those with a CCI < 3.
For example, among those with CCI =3, the risk of
cancer-specific death was 1.10 (95%CI: 0.93, 1.28),
1.81 (95%CI: 1.43, 2.29), 4.67 (95%CI: 3.05, 7.14),
and 6.97 (95%CI: 5.32, 9.14) for score=1, 2, 3 and 4
compared to score=0 (Table 4). The univariate asso-
ciation between the mortality score and the CCI did
not show a strong correlation between both mea-
surements (correlation coefficient: 0.15; P<0.001 and
kappa’s coefficient of agreement: 0.01; P<0.001).
A stratified analysis by race/ethnicity showed that the
score predicted mortality in a similar way for non-
Hispanic white, non-Hispanic blacks, and Mexican
American (Table 5). The results for cancer and circula-
tory death were also comparable with the findings in
Table 2.
Excluding those with follow-up of <1 year, as part of a
sensitivity analysis, showed similar patterns to those
observed in Table 2 (results not shown). For example,
the HRs for all-cause mortality increased with values of
the mortality score: 1.20 (95%CI: 1. 07, 1.34), 1.81 (95%
CI: 1.58, 2.08), 2.99 (95%CI: 2.33, 3.84), and 5.55 (95%
CI: 4.32, 7.14), for score=1, 2, 3 and 4 compared to
score=0. Similar observations were made when exclud-
ing those with follow-up <3 or <5 years (results not
shown).
Table 3 Age-group specific analysis: Hazard Ratio (HR) and 95% Confidence Intervals (CI) for risk of all cause,
cancer-specific, and circulatory disease death
Age-group <65 (N=9873) Age-group 65+ (N=3183)
All cause Cancer Circulatory All cause Cancer Circulatory
N=875 N=257 N=294 N=2,206 N=396 N=1094
HR 95%CI HR 95%CI HR 95%CI HR 95%CI HR 95%CI HR 95%CI
Score=0 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref
Score=1 1.21 0.96, 1.53 1.12 0.78, 1.61 1.51 0.93, 2.45 1.21 1.05, 1.40 1.13 0.87, 1.45 1.21 0.99, 1.47
Score=2 2.02 1.57, 2.61 1.37 0.74, 2.51 2.75 1.69, 4.49 1.88 1.65, 2.15 1.26 0.94, 1.70 2.00 1.68, 2.38
Score=3 3.34 2.11, 5.29 0.87 0.37, 2.05 4.15 1.61, 10.70 3.47 2.69, 4.47 3.81 2.38, 6.11 2.79 1.50, 5.18
Score=4 7.31 2.42, 22.01 4.24 0.94, 19.14 8.27 5.68, 12.05 8.47 5.58, 12.87 9.99 5.52, 18.08
P for trend <0.001 0.362 <0.001 <0.001 <0.001 <0.001
All models were adjusted for age, gender, poverty to income ratio, race ethnicity group, smoking behavior, alcohol consumption, vigorous physical activity, BMI,
and Charlson Comorbidity Index.
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Figure 1 Hazard ratio for risk of all-cause death by different values of the mortality score. The model was adjusted for age, gender,
poverty to income ratio, race/ethnicity, smoking behavior, alcohol consumption, vigorous physical activity, Charlson Comorbidity Index, and BMI.
Van Hemelrijck et al. BMC Public Health 2012, 12:895 Page 5 of 9
http://www.biomedcentral.com/1471-2458/12/895
Table 4 Hazard Ratio (HR) and 95% Confidence Intervals (CI) for risk of all-cause, cancer-specific, and circulatory death, stratified by Charlson Comorbidity
index
Total Men Women
All-cause Cancer Circulatory All-cause Cancer Circulatory All-cause Cancer Circulatory
HR 95%CI HR 95%CI HR 95%CI HR 95%CI HR 95%CI HR 95%CI HR 95%CI HR 95%CI HR 95%CI
Comorbidity Index <3
Score=0 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref
Score=1 1.30 1.07, 1.58 0.97 0.70, 1.36 1.47 1.09, 1.98 1.22 0.85, 1.58 1.30 0.91, 1.85 1.12 0.78, 1.60 1.41 1.00, 1.99 0.63 0.29, 1.36 2.15 1.21, 3.72
Score=2 1.85 1.45, 2.38 1.23 0.68, 2.21 2.73 1.68, 4.43 1.53 1.14, 2.00 0.83 0.50, 1.37 2.25 1.40, 3.62 3.05 2.05, 4.52 2.50 0.93, 6.71 4.30 1.94, 9.53
Score=3 3.16 2.03, 4.94 0.64 0.16, 2.50 1.06 0.30, 3.75 3.30 1.94, 5.64 0.63 0.12, 3.27 0.87 0.22, 3.44 1.89 0.52, 6.79 0.52 0.06, 4.84 1.32 0.08, 22.13
Score=4 13.32 6.15, 28.87 17.66 9.86, 31.64 11.27 5.72, 22.22 19.20 9.17, 40.20
P for trend <0.001 0.844 <0.001 0.002 0.938 0.009 <0.001 0.692 0.001
Comorbidity Index =3
Score=0 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref
Score=1 1.30 1.07, 1.57 1.31 0.87, 1.96 1.15 0.81, 1.62 1.18 0.93, 1.43 1.54 1.00, 2.37 1.43 1.06, 1.92 0.99 0.81, 1.19 0.84 0.43, 1.63 1.08 0.85, 1.39
Score=2 1.98 1.60, 2.44 1.29 0.80, 2.08 2.18 1.63, 2.90 1.81 1.08, 2.19 1.93 0.97, 3.85 1.35 0.99, 1.86 2.47 1.74, 3.50 1.04 0.44, 2.43 2.26 1.58, 3.23
Score=3 2.52 1.99, 3.18 3.27 2.07, 5.17 2.38 1.28, 4.41 3.57 3.57, 9.86 4.36 1.86, 10.23 5.96 2.10, 16.92 3.69 1.81, 7.55 6.66 1.97, 22.50
Score=4 10.22 5.08, 20.58 3.66 1.93, 6.95 16.55 6.66, 41.11 6.23 2.14, 15.81 0.64 0.09, 4.85 9.14 6.71, 12.46 9.36 3.73, 23.52 4.55 1.09, 18.99
P for trend <0.001 0.009 <0.001 <0.001 0.001 0.001 <0.001 0.777 <0.001
Comorbidity Index =4
Score=0 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref
Score=1 1.30 1.07, 1.58 0.97 0.70, 1.36 1.47 1.09, 1.98 1.22 0.85, 1.58 0.93 0.56, 1.56 1.07 0.71, 1.62 1.41 1.11, 1.78 1.72 0.88, 3.33 1.25 0.84, 1.86
Score=2 1.85 1.45, 2.38 1.23 0.68, 2.21 2.73 1.68, 4.43 1.53 1.14, 2.00 0.68 0.35, 1.35 2.04 1.29, 3.24 2.16 1.57, 2.98 2.06 0.98, 4.37 2.28 1.42, 3.65
Score=3 3.16 2.03, 4.94 0.64 0.16, 2.50 1.06 0.30, 3.75 3.30 1.94, 5.64 3.51 1.66, 7.44 3.85 1.79, 8.29 1.60 1.02, 2.53 3.04 1.41, 6.53 0.71 0.23, 2.20
Score=4 13.32 6.15, 28.87 17.66 9.86, 31.64 11.27 5.72, 22.22 10.76 5.29, 21.89 14.44 6.11, 34.15 5.85 2.61, 13.09 26.72 7.81, 91.37
P for trend <0.001 0.003 <0.001 <0.001 0.965 <0.001 <0.001 0.003 0.002
All models were adjusted for age, gender, poverty to income ratio, race ethnicity group, smoking behavior, alcohol consumption, vigorous physical activity, and BMI.
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Discussion
Using NHANES-III data we could replicate the results
of the Swedish AMORIS study [1]. The combination of
serum levels of CRP, albumin, GGT, and HDL was posi-
tively associated with mortality and was even predictive
in patients with low comorbidity based on CCI. Further-
more, the association between the score and mortality
was found to be similar among non-Hispanic whites,
non-Hispanic blacks, and Mexican Americans.
The three suggested mechanisms, inflammation, liver
dysfunction, and lipid metabolism, have been associated
with early death and comorbidities in several different
research settings. The inflammation-based Glasgow
Prognostic Score (GPS), based on serum levels of CRP
and albumin, has repeatedly been shown to be a pre-
dictor of survival, independent of tumor stage, perform-
ance status and treatment [3,18-20]. In a study of 540
cancer patients, increasing GPS correlated with more ag-
gressive tumor biology in terms of tumor size, presence
of lymph node metastasis, and higher tumor recurrence
rate [20]. In addition to being a marker of liver dysfunc-
tion, high levels of GGT (>28 U/L) have been found to
be positively associated with risk of all cause mortality
and risk of developing cancer [21,22]. It is also thought
that persistent production of reactive oxygen stress fol-
lowing increased GGT expression in tumor cells contri-
butes to genetic instability and tumor progression [19].
Finally, HDL cholesterol, as a component of the meta-
bolic syndrome, has been extensively studied in relation
to early death and comorbidities [12,23]. Apart from its
link with the lipid metabolism, HDL is also associated
with inflammation [6,23,24]. More specifically, HDL has
been linked with pro-inflammatory cytokines such as
tumor necrosis factor-α (TNF-α) [25]. It has been shown
that HDL reduces free TNF-α resulting in reduced tissue
damage, reduced infiltration of macrophages and neutro-
phils, and potential attenuated tumor formation [26]. A
prospective study of 989 persons aged 65 and over,
showed that high levels of HDL were significantly asso-
ciated with low total risk of death in men [27].
As in the Swedish AMORIS study, the HRs found
using data from NHANES III were also of a magnitude
that may be of clinical relevance. Even though Figure 1
did not show a clear pattern by specific markers of the
mortality score, albumin and GGT seemed to contribute
slightly more to the prediction of death than the other
markers. It is important to note that these results are
slightly different from our analysis based on continuous
levels of the four studied biomarkers, which is likely
explained by the more medically relevant cut-offs used
in our mortality score. The findings in Figure 1 suggest
that markers of inflammation and reactive oxygen spe-
cies are more strongly associated with risk of death. Be-
cause of limited sample size, it was not possible to
perform identical age-stratified analysis so that we could
not identify the predictive strength of the score in those
aged 50–65. In our analysis, the score was found to be
equally predictive of death among those younger and
older than 65. Interestingly, we also replicated the find-
ings stratified by categories of the CCI. Among those
with CCI<3, there was a positive trend between the mor-
tality score and all-cause mortality as well as circulatory
disease-specific death. The association was not statisti-
cally significant with cancer-specific death; this may be
due to the comparably small number of cancer deaths
(24 versus 42%). Nevertheless, the results by categories
of CCI indicate that the mortality score is predictive for
mortality over and above the prediction by CCI.
In our study we could also evaluate the mortality score
in different ethnic groups. A study evaluating the clinical
utility of the triglycerides-to-HDL ratio showed that this
ratio may identify insulin-resistance in Aboriginals,
Chinese, and Europeans, but not South Asians, thus
reflecting possible ethnic differences in normal lipid
Table 5 Hazard Ratio (HR) and 95% Confidence Intervals
(CI) for risk of all-cause, cancer-specific, and circulatory
death, stratified by race/ethnicity
Total
All-cause Cancer Circulatory
HR 95%CI HR 95%CI HR 95%CI
Non-Hispanic white
Score=0 1.00 Ref 1.00 Ref 1.00 Ref
Score=1 1.17 1.04, 1.31 1.03 0.83, 1.28 1.31 1.09, 1.57
Score=2 1.98 1.64, 2.39 1.25 0.88, 1.99 2.44 1.70, 3.03
Score=3 3.11 2.31, 4.19 1.39 0.88, 2.18 3.43 1.62, 7.26
Score=4 9.51 6.40, 14.14 7.80 5.09, 11.95 10.50 5.38, 20.47
P for trend <0.001 0.154 <0.001
Non-Hispanic black
Score=0 1.00 Ref 1.00 Ref 1.00 Ref
Score=1 1.45 1.23, 1.71 1.53 1.09, 2.15 1.30 1.04, 1.61
Score=2 1.77 1.38, 2.26 1.42 0.89, 2.29 1.49 1.02, 2.16
Score=3 4.86 3.38, 6.99 6.76 3.64, 12.55 3.19 1.77, 5.76
Score=4 3.76 1.41, 10.04 4.39 0.75, 25.52 2.46 0.46, 13.21
P for trend <0.001 <0.001 0.001
Mexican American
Score=0 1.00 Ref 1.00 Ref 1.00 Ref
Score=1 1.04 0.85, 1.27 0.55 0.26, 1.14 1.15 0.80, 1.65
Score=2 1.31 0.87, 1.98 0.47 1.19, 1.16 1.35 0.86, 2.10
Score=3 3.65 1.93, 6.89 3.40 0.95, 12.11 2.72 1.34, 5.52
Score=4 11.79 5.85, 23.78 14.45 6.17, 33.84
P for trend 0.002 0.356 0.007
All models were adjusted for age, gender, poverty to income ratio, smoking
behavior, alcohol consumption, vigorous physical activity, Charlson
Comorbidity Index, and BMI.
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levels [28]. Also, levels of albumin also differed by ethni-
city. Among UK resident patients of white European or
south Asian ethnicity with type 2 diabetes mellitus there
were significant differences in microalbuminuria [29]. In
addition, the association between CRP and disease out-
come appeared to be influenced by ethnicity. In a multi-
ethnic cohort including 2362 Caucasians, 1601 African
Americans, 1353 Hispanics, and 751 Chinese, CRP was
only associated with the risk of circulatory disease in
Caucasians [30]. This variation by ethnicity was smaller
for GGT. In another study based on NHANES III, the
correlation between GGT and risk of hypertension was
consistent by race-ethnicity [31]. In our study there was
also no effect-modification by race-ethnicity; the mortal-
ity score seemed to predict all cause, cancer-specific and
circulatory death in a consistent way across ethnic
groups. This may suggest that a combination of these
four biomarkers is more general and less susceptible to
subgroup differences.
This study has several strengths including its general-
izibility following the use of nationally representative
data. Therefore it was also possible in our analysis to
perform a stratified analysis by race/ethnicity. We were
able to adjust for many potential confounding factors
and examine interactions by age and the CCI. In a sensi-
tivity analysis, we used different medical cut-offs by sex
for HDL and GGT, but this did not materially alter our
findings (results not shown). Another limitation of this
study and the mortality score is that it relies on one sin-
gle measurement so that it may be prone to measure-
ment error and within-person variation. Repeated
measurements may strengthen the accuracy of the score.
In addition, it is important to note that the current mor-
tality score only represents a selection of mechanisms
and markers associated with early death. It is possible
that other markers such as hypertension or the ratio of
total to HDL cholesterol may also be good components
of a mortality score, however we believe that the current
mortality score already represents three important
mechanisms associated with early death. A next step in
the process of potentially taking this score in clinic is
the performance of sensitivity and specific tests in order
to determine the most predictive cut-offs for the differ-
ent biomarkers used.
Conclusion
The combination of four biomarkers predicted all-cause
mortality as well as cancer and circulatory disease-
specific death in NHANES III. This is in agreement with
a Swedish study and was consistent across different eth-
nic groups. This trans-ethnic validity and the positive as-
sociation for all categories of the CCI suggests that this
score may help clinicians making decisions in prevention
and disease management.
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